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CD4(+) but not CD8(+) lymphocytes in peripheral blood of 
lung cancer patients (p<0,05). We have also observed higher 
levels of the T-bet(+) and ROR-γt(+) CD4(+) lymphocytes with 
decreased level of the FoXP3 (+) CD4(+) cells (p<0,05), and 
accumulation of GATA-3(+) CD4(+) lymphocytes specific for 
TH2 immune response (p<0,05).  
 
 
Conclusions: PD-1 and CTLA-4 act as negative regulators of T 
cell activation (checkpoint antigens) and their enhanced 
expression may results from immunological overstimulation 
which may also be the cause of decreased percentage of 
regulatory T cells observed 12 weeks following SRBT. SBRT 
changes immune response towards Th2 phenotype. 
Correlation of these observations with the results of the 
treatment may make future trials, looking for factors 
predictive for response to immunotherapy, possible. 
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Purpose/Objective: Small-cell lung cancer (SCLC) has several 
characteristics that distinguish it from other lung cancers 
types, mainly its high propensity to disseminate and most 
particularly the high risk of brain failure. The incidence of 
brain metastases (BM) in SCLC is estimated at 10–14% at the 
time of initial diagnosis. Prophylactic cranial irradiation (PCI) 
has proven its efficacy, not only in terms of brain failure but 
also in terms of survival in patients with non metastatic and 
metastatic disease. More recent trials have also addressed 
the issue of the possible neurotoxicity of PCI. This study 
attempted to delineate the distribution of brain metastases 
with relation to the hippocampus for the purpose of exploring 
the viability of hippocampal sparing radiotherapy to 
potentially reduce neurocognitive deficits from radiation 
Materials and Methods: The pre-radiotherapy T1-weighted, 
contrast-enhanced axial MR images of 20 patients who had 
brain metastases of small-cell lung cancer in first-line 
chemotherapy between 2009 and 2014 were studied. Axial 
images were used to contour the hippocampus as well as 
each metastasis. The anatomic boundaries of the 
hippocampus were identified according to the RTOG 0933. 
We contoured brain metastases as well as hippocampi with  
5-, 10-, and 15-mm expansion envelopes. 
Results: Of 193 identified metastases, 3.1% (n =6) were 
located within 5 mm of the hippocampus, 2.1% (n=4) between 
5 and 10 mm and 3.1% (n=6) between 10 and 15 mm. Then, 
8.3% of our patients presented hippocampal or 
peri/hippocampal metastasis. Ninety-two percent of 
metastases were located greater than 15 mm from the 
hippocampus (n =177). 
Conclusions: In our study, 8.3% of patients had metastases 15 
mm around the hippocampus, or less. Hence, a 15-mm 
margin around the hippocampus for conformal avoidance 
whole brain radiotherapy represents an unacceptable risk of 
disease progression after hippocampal avoidance during 
prophylactic whole-brain radiotherapy for small cell lung 
cancer. 
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Purpose/Objective: Severe radiation induced esophagitis is a 
frequent side-effect of concurrent accelerated chemo-
radiation for small cell lung cancer (SCLC).  
Pre-treatment predictive models can facilitate identifying 
high-risk patients to provide intensive nutritional support or 
prophylactic placement of a naso-gastric feeding tube. 
Materials and Methods: We analyzed 240 consecutive 
patients with stage I-III SCLC from our prospective database, 
referred between December 2004 and March 2014 for 
concurrent platinum-etoposide and accelerated radiotherapy. 
All patients were FDG-PET-staged and received 45 Gy in 1.5 
Gy fractions twice daily to the tumor and PET-positive or 
pathologically proven lymph nodes. 97% of patients received 
concurrent chemo-radiation as planned, the remaining 3% of 
patients were treated sequentially. A total of 47 patients 
(20%) experienced dysphagia grade ≥3 (CTCAE 4.0). 
A set of clinical (e.g. cT-stage, cN-stage, age, gender, WHO-
PS, smoking status,...), biochemical (platelet count, 
hemoglobin and LDH at diagnosis) and radiotherapy planning 
parameters (e.g. mean (Dmean) and maximal dose (Dmax) to 
the esophagus, GTV,...) of potential relevance for esophagitis 
was retrieved for each patient.  
We developed three distinct prediction models for dysphagia 
grade ≥3:  
Model 1: based on classical clinical/ biochemical factors only. 
Model 2: based on the same set of parameters as Model 1, 
but replacing the classical nodal parameters (cN-stage, cN3-
stage) investigated for model 1 by the number of treated 
nodal stations with close proximity to the esophagus (``High 
Risk stations``: 1L, 1R, 3P, 4L, 7, 8 and 9). 
Model 3: based on both classical clinical/ biochemical and 
planning parameters.  
A bootstrap approach was used to assess how many variables 
should be included in the models: 2 or 3 variables for model 
1, 3 for model 2 and 4 for model 3. 
For each model individually the strongest combination of 
parameters from the data-set was composed using a 
backward selection procedure based on Akaike's Information 
Criterion (AIC). 
Results: For Model 1 the following variables were statistically 
significant: cT4 (yes/no), platelet count and gender. cN-stage 
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did not contribute significantly and was thus not 
incorporated.  
Model 2 incorporated the number of ``High Risk nodal 
stations``(0, 1-2 or ≥3), gender and cT4.  
Model 3 comprised esophageal Dmean and Dmax, gender and 
total GTV. 
Model 1 had an AUC of 0.62, which decreased to 0.58 after 
correction for overfitting. Model 2 yielded an AUC of 0.73 
(corrected for overfitting: AUC=0.70) and model 3 had an 
AUC of 0.69 (corrected for overfitting: 0.67). 
In a secondary analysis, the number of nodal stations close to 
the esophagus correlated with esophageal Dmean and Dmax: 
0.53 (p<0.001) and 0.40 (p<0.001), respectively. 
Conclusions: In SCLC patients referred for treatment with 
accelerated concurrent chemo-irradiation, a predictive 
model for esophagitis grade ≥3 using only clinical variables 
(gender, number of nodal stations close to the esophagus and 
cT4-stage) performs at least as well as a model incorporating 
planning parameters. This allows clinicians to directly 
identify high-risk patients. External validation is ongoing.  
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Purpose/Objective: Esophagitis are one of the acute 
treatment related toxicities to definitive radiotherapy for 
NSCLC. Most current researches about the risk factors for 
acute esophagitis are based on 3DCRT. The purpose of this 
study was to estimate the dose-effect relationship between 
esophagitis and clinical and dosimetric parameters in the 
patients with local advanced NSCLC receiving IMRT and 
concomitant chemotherapy (CCT). 
Materials and Methods: Between 2009 and 2013, 117 
patients with stages IIB-IIIB NSCLC enrolled in the multi 
institution clinical trial NARLAL. All patients were treated 
with 2 cycles of induction chemotherapy followed by IMRT 
and CCT (fixed dose of vinorelbine 50 mg three times per 
week). The maximal esophagitis grade was prospectively 
scored using the Common Toxicity Criteria 3.0. Clinical and 
dosimetric variables were analyzed for the correlation with 
grade ≥2 esophagitis though multivariable logistic regression. 
The optimal dose metrics were chosen using Akaike 
Information Criterion (AIC). All models included one dose 
position parameter, one dosimetric parameter, gender, and 
institution. Dose position was defined as the average relative 
position (zero at start of esophagus and one at the end) 
irradiated above a certain dose. The dose variable was either 
maximum dose, mean dose, the physical length of esophagus 
irradiated above a specific dose (Lx), or the relative volume 
of esophagus irradiated above a specified dose (Vx). To 
validate the impact of the fixed dose of vinorelbine, the body 
surface area was also tested within the models. Data are 
those collected July 2014 and will be updated. 
Results: Grade 1 esophagitis was experienced by 50 (43%), 
grade 2 by 30 (26%), and grade 3 by 10 (8%) patients, 
respectively. The dose parameter in the two models with 
lowest AIC was the relative volume irradiated above 40 Gy 
(V40) (OR=2.39 per additional 10% volume, p<0.001) or length 
of esophagus irradiated above 40 Gy (L40) (OR=4.76 per 
additional 5 cm, p<0.001). The dose position parameter for 
these two models were the average position of esophagus 
irradiated above 20 Gy (P20)(OR=0.37 in V40 Model and 0.45 in 
L40 model per 0.1 relative unit, p=0.002 and 0.011), thus 
irradiation of the upper part of esophagus were more toxic 
than the lower part. The gender was highly significant in both 
models (OR=11.99 in V40 model and 12.45 in L40 model, 
p<0.001) with the female gender experiencing more toxicity. 
Body surface area was not significant in a multivariable 
analysis neither together with the gender variable, nor within 
the two genders separately. 
Conclusions: V40 and L40 were the most effective dosimetric 
predictors of grade 2 or greater acute esophagitis in NSCLC 
patients treated with IMRT and CCT. The position of 
irradiation region of the esophagus showed also to be 
significantly correlated with acute esophagitis. The high OR 
for gender could be somewhat confounded by the body 
surface area. However, the analyses did not support a 
confounding effect. 
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Purpose/Objective: Angiotensin converting enzyme inhibitors 
(ACEi) and angiotensin receptor blockers (ARBs) have been 
shown to decrease the incidence of symptomatic radiation 
pneumonitis (RP) in both the pre-clinical and clinical setting. 
Previously reported outcomes, however, have primarily been 
in the setting of conventionally fractionated radiotherapy; 
similar effects have yet to be established in lung stereotactic 
body radiotherapy (SBRT). The purpose of this study was to 
examine the effect of using an ACEi/ARBs during SBRT on the 
incidence of RP. 
Materials and Methods: 321 patients who received LINAC-
based lung SBRT from January 2008 to June 2013 for early 
stage NSCLC or oligometastases of the lung were identified in 
a prospectively maintained institutional database. Patients 
who received previous thoracic radiation therapy and/or lung 
surgery were excluded. Overall survival (OS) was calculated 
by Kaplan-Meier method. Pulmonary toxicity was assessed 
using the Common Terminology Criteria for Adverse Events, 
v4.03. Statistical comparisons utilized univariate and 
multivariate Cox regression to evaluate the impact of patient 
factors as well as dose-volume histogram parameters on the 
incidence of symptomatic, grade 2 or greater, RP. 
Results: Median follow up time was 13.9 months. Median age 
was 74 years (range, 47-90). Median radiation dose was 54 Gy 
(range, 45-60) with the median number of fractions being 3 
(range, 3-12). The median volume of normal lung that 
received 20 Gy (V20) was 5.5% (range, 1-30). 64 patients had 
a centrally located tumor less than 2 cm from the 
bronchopulmonary tree (19.9%). Two year actuarial OS was 
57.1%. 132 patients were using an ACEi/ARBs at the time of 
receiving SBRT (41.1%); 98 patients were using an ACEi 
(30.5%). Overall, 17 patients had symptomatic RP (5.3%). 
There was no difference in the incidence of RP with 
